Angela Koehler

Angela Koehler is a Professor of Biological Engineering at MIT, affiliated with the Koch Institute and MIT Health and Life Sciences Collaborative. She leads initiatives in precision cancer medicine and drug discovery, focusing on 'undruggable' cancer proteins. Her lab develops chemical tools targeting transcription factors and oncogenic pathways.

• Associate Director at Koch Institute
• Member of MIT Center for Precision Cancer Medicine
• Institute Member at Broad Institute of MIT/Harvard

Research focuses on modulating transcriptional networks via small molecules and targeted protein degradation. Key areas include CDK9 inhibition, RNA-binding proteins, and cytokine therapeutics. Koehler has founded four biotech firms (Ligon Discovery, Kronos Bio, 76Bio, Samori Bio) and advises major pharmaceutical companies.

Education: PhD in Chemistry (Harvard, 2003), BS in Biochemistry (Reed College, 1997). Awards include NSF CAREER Award (2020), Ono Pharma Breakthrough Science Award (2022), and Novartis Lectureship (2021).